$LFMDP
Immudyne, Inc.
CIK:0000948320|SEC Filings
Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Income Statement [Abstract] | ||||
| Telehealth revenue, net | $ 47,281,085 | $ 49,018,882 | $ 97,444,041 | $ 99,906,781 |
| Cost of telehealth revenue | 5,284,323 | 6,838,703 | 11,209,822 | 14,975,164 |
| Gross profit | 41,996,762 | 42,180,179 | 86,234,219 | 84,931,617 |
| Expenses | ||||
| Selling and marketing expenses | 28,035,947 | 22,151,114 | 57,910,807 | 44,424,036 |
| General and administrative expenses | 13,645,809 | 14,439,140 | 28,822,164 | 28,779,294 |
| Other operating expenses | 3,040,187 | 2,883,015 | 6,220,133 | 5,272,551 |
| Customer service expenses | 2,612,986 | 3,230,735 | 5,752,291 | 6,302,229 |
| Development costs | 1,791,434 | 1,823,061 | 3,587,497 | 3,682,110 |
| Total expenses | 49,126,363 | 44,527,065 | 102,292,892 | 88,460,220 |
| Operating loss from continuing operations | (7,129,601) | (2,346,886) | (16,058,673) | (3,528,603) |
| Interest income (expense), net | 45,660 | (660,787) | 102,136 | (1,124,425) |
| Loss from continuing operations before income taxes | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) |
| Income tax provision | ||||
| Net loss from continuing operations | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) |
| Net income from discontinued operations | 1,893,084 | 3,886,506 | ||
| Net loss | (7,083,941) | (1,114,589) | (15,956,537) | (766,522) |
| Net income attributable to non-controlling interest of discontinued operations | 505,075 | 1,036,920 | ||
| Net loss attributable to LifeMD, Inc. | (7,083,941) | (1,619,664) | (15,956,537) | (1,803,442) |
| Preferred stock dividends | (776,562) | (776,562) | (1,553,125) | (1,553,125) |
| Net loss attributable to LifeMD, Inc. common stockholders | $ (7,860,503) | $ (2,396,226) | $ (17,509,662) | $ (3,356,567) |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders: | ||||
| Continuing operations | $ (0.16) | $ (0.09) | $ (0.37) | $ (0.14) |
| Discontinued operations | 0.03 | 0.07 | ||
| Basic loss per share | (0.16) | (0.05) | (0.37) | (0.08) |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders: | ||||
| Continuing operations | (0.16) | (0.09) | (0.37) | (0.14) |
| Discontinued operations | 0.03 | 0.07 | ||
| Diluted loss per share | $ (0.16) | $ (0.05) | $ (0.37) | $ (0.08) |
| Weighted average number of common shares outstanding: | ||||
| Basic | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |
| Diluted | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |
Consolidated Balance Sheets - USD ($) |
Jun. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Current Assets | ||
| Cash | $ 25,141,615 | $ 36,786,318 |
| Accounts receivable | 11,256,158 | 9,305,277 |
| Product deposit | 243,759 | 320,217 |
| Inventory, net | 2,956,144 | 2,773,576 |
| Other current assets | 2,486,803 | 2,646,077 |
| Total Current Assets | 42,084,479 | 51,831,465 |
| Non-current Assets | ||
| Equipment, net | 2,035,475 | 2,444,717 |
| Right of use assets, net | 4,839,958 | 5,267,857 |
| Capitalized software, net | 10,734,486 | 10,604,946 |
| Intangible assets, net | 198,500 | 262,334 |
| Total Non-current Assets | 17,808,419 | 18,579,854 |
| Total Assets | 59,892,898 | 70,411,319 |
| Current Liabilities | ||
| Accounts payable | 18,156,912 | 14,149,154 |
| Accrued expenses | 16,961,186 | 15,974,016 |
| Current operating lease liabilities | 699,511 | 642,422 |
| Deferred revenue | 10,791,221 | 10,807,773 |
| Total Current Liabilities | 46,608,830 | 41,573,365 |
| Long-term Liabilities | ||
| Noncurrent operating lease liabilities | 5,317,613 | 5,681,374 |
| Total Liabilities | 51,926,443 | 47,254,739 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ Equity | ||
| Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $35.8 million as of June 30, 2026 and December 31, 2025 | 140 | 140 |
| Common Stock, $0.01 par value; 100,000,000 shares authorized, 47,923,532 and 46,760,016 shares issued, 47,820,492 and 46,656,976 outstanding as of June 30, 2026 and December 31, 2025, respectively | 479,235 | 467,600 |
| Additional paid-in capital | 253,763,518 | 251,455,616 |
| Accumulated deficit | (246,112,737) | (228,603,075) |
| Treasury stock, 103,040, at cost, as of June 30, 2026 and December 31, 2025 | (163,701) | (163,701) |
| Total Stockholders’ Equity | 7,966,455 | 23,156,580 |
| Total Liabilities and Stockholders’ Equity | $ 59,892,898 | $ 70,411,319 |